{"id":"W2295354328","doi":"10.1016/s1470-2045(15)00614-2","title":"Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial","year":2016,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":470,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; Ignyta; National Institutes of Health; University of Washington; Astex Pharmaceuticals; Eli Lilly and Company; Novartis Institutes for BioMedical Research; Ariad Pharmaceuticals; Genentech; Pfizer; Novartis Pharmaceuticals Corporation; Chugai Pharmaceutical; Servier; Universität Heidelberg","keywords":"Ceritinib; Crizotinib; Medicine; ALK inhibitor; Internal medicine; Anaplastic lymphoma kinase; Lung cancer; Oncology; Tyrosine-kinase inhibitor; Clinical trial; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003047984,0.0001382181,0.0005039352,0.00002311775,0.00008770997,0.00001042963,0.0001949395,0.00008004157,0.00008471293],"category_scores_gemma":[0.00006688003,0.0000582566,0.00001787895,0.0001232845,0.0001451938,0.00007634992,0.00008798479,0.0001502305,0.000002405981],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002259929,"about_ca_system_score_gemma":0.0003442295,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.004069437,"about_ca_topic_score_gemma":0.003748997,"domain_scores_codex":[0.9988525,0.0002391814,0.0002672332,0.0002678013,0.0001235645,0.0002497243],"domain_scores_gemma":[0.9986581,0.0005590025,0.0002458317,0.0003847432,0.00009096927,0.00006132015],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7888225,0.006001228,0.09214197,0.00003862979,0.0008099222,0.00002769007,0.004775498,0.000003923829,0.005153148,0.00002364089,0.006076131,0.09612568],"study_design_scores_gemma":[0.7484642,0.002224434,0.2360903,0.0002249483,0.0005978648,9.232241e-7,0.0001359563,0.00007396033,0.001007501,0.000008897867,0.01105976,0.0001113241],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9830551,0.0001323248,0.00002001965,0.009349887,0.0001864919,0.002628687,0.00122665,0.00001243212,0.003388473],"genre_scores_gemma":[0.9980693,0.0003371984,0.00028475,0.0005450668,0.0002039483,0.0001543595,0.0001212141,0.00001593756,0.0002681925],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1439483,"threshold_uncertainty_score":0.6151798,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04046967010096525,"score_gpt":0.3862219429664884,"score_spread":0.3457522728655231,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}